Back HIV Treatment Approved HIV Drugs

Approved HIV Drugs

AIDS 2014: Single-tablet HIV Regimens Not Necessarily More Durable

Antiretroviral therapy (ART) regimens consisting of 1 pill taken once-daily -- known as single-tablet regimens -- were not associated with a longer time to treatment discontinuation when compared to some other modern, well-tolerated regimens that involve more pills or twice-daily dosing, according to a study presented at the 20th International AIDS Conference last month in Melbourne.

alt

Read more:

AIDS 2014: Switching ART with Suppressed Viral Load Linked to Treatment Failure

People who switch away from their initial antiretroviral therapy (ART) regimen when their viral load is undetectable may have a higher likelihood of subsequent virological failure, researchers reported at the 20thInternational AIDS Conference last week in Melbourne. However, the association varied across groups and the researchers suggested their findings may reflect issues such as adherence difficulties or treatment changes due to pregnancy.

alt

Read more:

AIDS 2014: Maraviroc Fails To Match Truvada for First-Line HIV Treatment

A NRTI-sparing dual antiretroviral regimen containing maraviroc (Selzentry) plus ritonavir-boosted darunavir (Prezista) was found to be less effective than a standard combination with tenofovir/emtricitabine (the drugs in Truvada), according to findings from the MODERN study presented this week at the 20th International AIDS Conference in Melbourne.

alt

Read more:

AIDS 2014: Dolutegravir Demonstrates Good Efficacy Despite Resistance

Antiretroviral regimens containing the recently approved HIV integrase inhibitor dolutegravir (Tivicay) demonstrated high rates of viral suppression even in treatment-experienced people who were resistant to NRTIs. Among people starting treatment for the first time, no resistance was detected through 96 weeks, according to study findings presented at the 20th International AIDS Conference last week in Melbourne.

alt

Read more:

People on First HIV Protease Inhibitor May Not Need to Switch After Single Treatment Failure

People with HIV who experience a single episode of virological failure while on their first protease inhibitor can safely stay on the same regimen without risk of disease progression, according to a study described in the May 19, advance edition of Clinical Infectious Diseases.

alt

Read more: